Latest by Rod McCullom

With Global Trials Expanding, More HIV Vaccines Are Put to the Test

An HIV vaccine has remained elusive. But a set of new strategies in trials around the world may finally turn that around. Rod McCullom reports.

By Rod McCullom

HIV Vaccines 101: How Vaccines Work

Vaccines are the most effective means to prevent and even eradicate infectious diseases. Learn the basics of how vaccines work, and the possible routes to a vaccine for HIV.

By Rod McCullom

Emerging Gonorrhea Antibiotic Resistance Could Lead to Incurable Strain, Experts Warn

"History shows us that bacteria will find a way to outlast the antibiotics we're using to treat it. We are running just one step ahead in order to preserve the remaining treatment option,” says Jonathan Mermin of CDC.

By Rod McCullom

Where Are the PrEP Interventions for People Who Inject Drugs?

PrEP is gaining steam in social media, hook up apps and public health efforts. But one community has been largely absent from this new era of HIV prevention: people who inject drugs. Rod McCullom reports.

By Rod McCullom

As Hepatitis C Goes Rural, Public Health and Medicine Strain to Adapt

Hep C was on the decline in the U.S. But between 2006 and 2012, rates more than tripled across Kentucky, Tennessee, West Virginia and Virginia. Rod McCullom reports on the challenges of an increasingly rural epidemic.

By Rod McCullom

HIV on the Agenda at #M4BL, the National Movement for Black Lives Convening

"We thought it was important to discuss HIV in the larger context of black activism and social justice work," explained Kenyon Farrow of Treatment Action Group. "We have a history of 30 years of activism around this issue."

By Rod McCullom

Black MSM, PrEP Access Top Focus of New CDC HIV Prevention Funding

In the week when, 34 years ago, The New York Times reported the first cases of what became known as HIV/AIDS, CDC awarded more than $216 million for five years of prevention efforts. The efforts will focus on gay, bisexual and other men who have se...

By Rod McCullom

Hedge Fund Billionaires Are New Target for Hepatitis C Cure Protests

The high cost of hepatitis C treatment has inspired lawsuits and protests. Now, activist have targeted the hedge fund investors who they say are reaping profits from the pricey pills. Rod McCullom reports.

By Rod McCullom

Discarded Syringes Reveal Stigma's Role in Growing Opiate and Hepatitis Epidemics

As small town and rural opiate use continues to rise, Daniel Raymond of the Harm Reduction Coalition says communities should provide safe disposal rather than lay blame.

By Rod McCullom

What's So Controversial About AIDS Healthcare Foundation?

A whistleblower lawsuit against the provider of HIV/AIDS care will take time to resolve. However, its filing has brought new attention to AIDS Healthcare Foundation's history, business and media practices and what some have called aggressive tactics....

By Rod McCullom